Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours By Ogkologos - October 25, 2024 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... June 15, 2022 ¿Qué son los biosimilares para el tratamiento del cáncer? November 30, 2021 Researchers at Purdue Create Filler That May Help Regenerate Tissue in... March 9, 2021 Load more HOT NEWS FDA Approves Relugolix for Advanced Prostate Cancer GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... Mom Who Lost Child Donates Breast Milk To Mom With Cancer Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS...
